Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BX-001N Phase 1 SAD/MAD in healthy participants
NCT06097702Phase 1Completed
- Sponsor
- Bilix
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Brixelle in ischemia-reperfusion injury (IRI) (3 arms), sponsored by Bilix. Primary endpoints: Treatment Emergent Adverse Events at Day 14, Clinical Laboratory Abnormalities at Day 14 and 2 more. Started Nov 2023; status: completed.
02
Drugs
Brixelle
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT06097702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06097702.